237 related articles for article (PubMed ID: 22731934)
1. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Hartung DM; Middleton L; Svoboda L; McGregor JC
CNS Drugs; 2012 Aug; 26(8):707-16. PubMed ID: 22731934
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
3. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
4. The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Duh MS; Andermann F; Paradis PE; Weiner J; Manjunath R; Crémieux PY
Dis Manag; 2007 Aug; 10(4):216-25. PubMed ID: 17718660
[TBL] [Abstract][Full Text] [Related]
5. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
6. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
7. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
8. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O
Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941
[TBL] [Abstract][Full Text] [Related]
11. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
12. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study.
Polard E; Nowak E; Happe A; Biraben A; Oger E;
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769
[TBL] [Abstract][Full Text] [Related]
13. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
14. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
[TBL] [Abstract][Full Text] [Related]
15. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
Yamada M; Welty TE
Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
[TBL] [Abstract][Full Text] [Related]
16. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
17. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
Lessing C; Ashton T; Davis P
Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
19. The risks and costs of multiple-generic substitution of topiramate.
Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J
Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520
[TBL] [Abstract][Full Text] [Related]
20. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E
Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
